Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Evaluating NALIRIFOX Versus Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

NCT07076212 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.

NCT NCT07076212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07076212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Evaluating NALIRIFOX Versus Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Medical University of South Carolina
Phase
Phase 2
Overall status
Recruiting
Start date
April 2, 2026
Completion date
November 30, 2029
Enrollment
52 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced pancreatic adenocarcinoma, metastatic pancreatic adenocarcinoma